Kornimate/medical-research-clean huggingface dataset:
acute congestive heart failure urgent care evaluation

Conditions: Heart Failure

Summary: this prospective validation study evaluates the ability of a risk algorithm, which can simultaneously predict the risk of death at 7 days and 30 days for patients with acute heart failure presenting to the emergency department. the risk algorithms for prediction of 7-day (emergency heart failure mortality risk grade \[ehmrg\]) and 30-day mortality (ehmrg30-st) have been previously derived.


Eligibility criteria:
inclusion criteria: * patients with acute heart failure diagnosed in the emergency department exclusion criteria: * palliative or do-not-resuscitate (dnr) directive * dialysis dependent
effectiveness of binge eating disorder treatments

Conditions: Eating Disorders

Summary: this study will evaluate the long-term effectiveness of interpersonal psychotherapy, behavioral weight loss interventions, and guided self help treatments in treating binge eating disorder (bed).

bed is a serious condition that is associated with psychiatric comorbidity, psychosocial impairment, and obesity. interpersonal psychotherapy (ipt), behavioral weight loss (bwl) interventions, and guided self help (gsh) treatments for bed have been evaluated, but the safest and most effective treatment has not yet been identified. this study will determine which of these three treatments is most effective in treating bed. participants are stratified by negative affect subtype and are randomly assigned for 6 months to one of three treatment groups: ipt, bwl, or gsh. ipt focuses on current interpersonal problems which are hypothesized to increase negative affect and lead to binge eating. bwl interventions involve the adoption of weight loss inducing behaviors. gsh is a shortened version of cognitive behavioral therapy that focuses directly on eating behavior. ipt and bwl patients have 20 treatment sessions; those receiving gsh have 10 sessions. assessments are made pre-treatment, post-treatment, and at 6, 12, 18, and 24 months after treatment is complete.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for binge eating disorder * body mass index (bmi) between 27 and 45 exclusion criteria: * body mass index \> 45 * current psychosis * current bipolar disorder * alcohol or drug dependence within last 6-months

Keywords: weight loss
renew clinic cohort study

Conditions: Hypertension; Prehypertension; Obesity; Overweight; Left Ventricular Hypertrophy; Elevated Blood Pressure

Summary: this is an ongoing, prospective cohort study of children and young adults who are evaluated in the reversing the negative effects of weight on the heart (renew) clinic at johns hopkins university. demographic and clinical data of patients who agree to participate are obtained via chart review and entered into a longitudinal clinic registry.


Eligibility criteria:
inclusion criteria: * children and young adults with overweight or obesity referred for evaluation of elevated blood pressure in the renew clinic at johns hopkins university are eligible. exclusion criteria: * children who are wards of the state or who are non-english speaking without an in-person interpreter accompanying them to the clinic visit.
a study to assess cyp3a4 modulator, oral contraceptive, and ph modifier drug interactions for abi-h2158 in healthy adults

Conditions: Chronic Hepatitis B

Summary: this study is designed to assess 1) the effect of multiple doses of itraconazole (cyp3a4 inhibitor), rifampin (cyp3a4 inducer), and esomeprazole (ph modifier) on the pharmacokinetics of a single oral dose of abi-h2158, and 2) the effect of steady-state oral abi-h2158 on the pharmacokinetics of midazolam (sedative) and levonorgestrel/ethinyl estradiol (active oral contraceptive) in healthy adult participants.


Eligibility criteria:
inclusion criteria: 1. no clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening. 2. cohort 5: naive to the use of oral contraceptives. exclusion criteria: 1. positive test results for human immunodeficiency virus (hiv) or hepatitis b or c.
radiation therapy alone for the treatment of stage 1 and 2 mucosa-associated lymphoid tissue (malt) lymphoma

Conditions: Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Extranodal Marginal Zone Lymphoma

Summary: this trial studies the side effects of radiation therapy used alone, and if it can achieve a high cure rate in the treatment of patients with malt lymphoma. radiation therapy uses high energy sources to kill cancer cells and shrink tumors. this treatment may improve the patient's lymphoma.

primary objective: i. to determine the efficacy and toxicity of radiation therapy alone in treating stage 1 and 2 malt lymphoma for newly diagnosed patients and for the patients who failed other treatment modalities. outline: patients undergo radiation therapy once daily (qd) 5 times weekly over 3.5-5 weeks. after completion of study treatment, patients are followed up at 6-8 weeks, and then every 3-4 months for year 1, every 4-6 months for year 2, every 6 months for years 3 and 4, and once yearly thereafter.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed stage 1 and 2 malt lymphoma are eligible for this study * patients with helicobacter (h.) pylori positive gastric malt lymphoma are recommended to have treatments with antibiotics prior to enrollment to this protocol * patients who failed other treatment modalities (e.g. chemotherapy, antibiotics therapy etc) are also eligible as far as they never had stage 3 or 4 disease during the course of the disease or disease progression to the opposite side of the diaphragm (as the time course of the response to antibiotic therapy can be very variable among patients, sometimes requiring more than one year for complete response, failure to antibiotic therapy can be very variable among patients, sometimes requiring more than one year for complete response, failure to antibiotic treatment will be defined as no response or progression of the disease documented by endoscopy and biopsy) * patients who have had stage 4 diseases due to bilateral parotid gland or ocular/ocular adnexal involvement or due to multiple sites within waldeyer's ring will still be eligible exclusion criteria: * patients who had previous radiation dose to the site of the current primary disease which would lead to violation of known radiation tolerance limit of that particular site if treated again * patients with malt lymphoma of the skin whose lesions are separated by more than 5 cm will be ineligible * previous or concurrent malignancy in any form would not be an exclusion criterion. however, patients who receive chemotherapy for concurrent malignancy will be excluded from statistical analysis * low blood cell counts would not be exclusion criteria as far as the patient is willing to accept supportive measures such as transfusions, filgrastim and epoetin
an investigational study to evaluate experimental medication bms-986165 compared to placebo in participants with plaque psoriasis (poetyk-pso-3) in mainland china, taiwan, and south korea

Conditions: Psoriasis

Summary: the purpose of this study is to investigate the experimental medication bms-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland china, taiwan, and south korea


Eligibility criteria:
inclusion criteria: * plaque psoriasis for at least 6 months * moderate to severe disease * candidate for phototherapy or systemic therapy exclusion criteria: * other forms of psoriasis * history of recent infection * prior exposure to bms-986165 other inclusion/exclusion criteria may apply.
postoperative nsclc treated with integrated medicine base on circulating tumor cell detection

Conditions: NSCLC

Summary: objective: to study the effect of jinfukang koufuye combined with chemotherapy on preventing relapse and metastasis of early postoperative nsclc patients. method: in this multicenter、prospective、randomized controlled clinical trial, 144 nsclc patients with complete resection、stage ib-iib were randomly divided into jinfukang koufuye combined with chemotherapy group (treatment group, n=72) and chemotherapy only group (controlled group, n=72). peripheral blood ctcs and immune cells were detect on five different time points: after operation、4 chemotherapy cycles were over、12 months after operation、18 months after operation、and 24 months after operation. to evaluate the effect of jinfukang koufuye combined with chemotherapy on the level of peripheral blood ctcs、dfs、immune function、quality of life of postoperative patients; and decreasing the side effect of chemotherapy.


Eligibility criteria:
inclusion criteria: 1. pathology-confirmed diagnosis of primary nsclc with complete resection, and stage ib-iib 2. accept chemotherapy for the first time 6 weeks after operation 3. age of 18-75 years old 4. eastern cooperative oncology group-ps≤2 5. n\>1.5×109/l、plt\> 100 × 109/l、hb\>100g/dl、liver and kidney function is normal or elevated ≤ 1.5 times 6. voluntary participation in the prospective study with signed informed consent exclusion criteria: 1. no pathology-confirmed diagnosis patients 2. patients with overall survival time\<6 months 3. patients with serious diseases like heart、liver、kidney and hematopoietic system at the same time 4. pregnant or breast feeding patients 5. patients with uncontrollable mentally disease 6. patients with diabetes
add-on therapy with edupression.com® on therapy resistant depressive patients treated with nasal esketamine spray

Conditions: Major Depressive Disorder; Therapy Resistant Depression

Summary: pragmatic clinical trial of an add-on therapy regarding the use of edupression.com® - a licensed computer based self-help program - on patients with therapy-resistant depression receiving esketamine nasal spray

edupression.com® - is a medical product and computer based self-help program based on cognitive behavioral therapy, psychoeducation and mood tracking. patients included in the interventional arm of this study are receiving full access to edupression.com®. due to limited resources regarding face-to-face therapy and a high prevalence of major depressive disorder - of which 37% can be identified as therapy-resistant depression (trd) according to the definition of the european medical agency (ema) - low-intensity psychosocial interventions such as edupression.com® are recommended as first-line digital therapeutic agent by international guidelines such as national institute for health and care excellence (nice) guidelines. studies have shown that digital interventions - such as edupression.com - show comparable clinical efficiency to face-to-face therapy and therefore could be able to fill the gap in limited ressources. in this study patients with therapy-resistant depression are receiving therapy with edupression.com® in addition to their treatment-as-usual with esketamine nasal spray. comparable studies have shown that patients receiving psychotherapy in addition to their medical therapy benefit in regards to their clinical outcome. considering these findings, this study is aimed to investigate potential clinical benefits in patients receiving digital therapy with edupression®.com as an add-on therapy to their treatment-as-usual therapy with esketamine nasal spray.

Eligibility criteria:
inclusion criteria: * age 18 or older * initial madrs-score of 22 or above * diagnosis of a therapy-resistant depression following the definition of the european medicines agency (ema) - absence of remission after two or more guideline-oriented therapies * patients assigned to treatment with nasal esketamine spray spravato® * signed informed consent * native german speaker * basic knowledge in using computers/smartphones operationalized as daily use of at least two devices (such as tablets, computers, smartphones etc) exclusion criteria: * contraindication regarding the use of spravato® * diagnosis of one of the following psychiatric comorbidities: substance abuse, schizoaffective disorders, schizophrenia, bipolar disorder, organic disorders diagnosed via mini international neuropsychiatric interview (mini)

Keywords: depression esketamine treatment resistant depression internet-based intervention telemedicine
long-term outcomes among patients with programmed death-ligand 1 <1% metastatic non-small cell lung cancer treated with first-line nivolumab + ipilimumab + 2 cycles of chemotherapy

Conditions: Metastatic Non-small Cell Lung Cancer

Summary: the study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (pd-l1) \<1% metastatic non-small cell lung cancer (mnsclc) treated with first-line (1l) nivolumab + ipilimumab + 2 cycles of chemotherapy (nic) in the us


Eligibility criteria:
inclusion criteria: * at least 18 years old at confirmed diagnosis with metastatic non-small cell lung cancer (nsclc) (stage iv), squamous or non-squamous histology * initiated first-line (1l) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (nic) regimen between 01 january 2018 and 2 years prior to study launch * tumor programmed death-ligand 1 (pd-l1) negative expression (i.e., pd-l1 \<1%) * no egfr, alk, or ros1 genetic mutation (i.e., wild type) * minimum of 6 months of follow-up after initiation of 1l nic\* exclusion criteria: • any prior systemic therapy for metastatic non-small cell lung cancer (nsclc)

Keywords: metastatic non-small cell lung cancer
ibuprofen concentration in cerebro spinal fluid (csf) of infants and children

Conditions: Fever

Summary: ibuprofen, the active ingredient in nurofen and advil, is a commonly used drug in children. there is very limited data about ibuprofen concentrations in the cerebro spinal fluid (csf). the objective of the current study is to describe concentrations of ibuprofen in the csf of infants and children after administration of ibuprofen. we will study infants presenting to the emergency department (ed) with fever who received ibuprofen. a complete sepsis workup including sampling of blood and csf is conducted in cases of suspected meningitis. we will measure ibuprofen in the blood and csf obtained during the sepsis workup. a better understanding of the pharmacokinetics of ibuprofen and its penetration into the csf will unable us to suggest more accurate dosing guidelines, and to better predict the effects of this commonly used drug.


Eligibility criteria:
inclusion criteria: * age: 3 month-18 years * rectal temperature \> 38.0oc or oral temperature \> 37.6 oc measured in the ed or at home. * a sepsis work up is indicated * at least one dose of ibuprofen was given in the last 8 hours prior to lumbar puncture (lp) exclusion criteria: * hypersensitivity to ibuprofen * known metabolic disorder * known liver or kidney disease * hydrocephalus * informed consent could not be obtained from a legal guardian

Keywords: fever ibuprofen
determine whether glycemic control is different between lantus & a 3rd oral agent when failure with other treatment

Conditions: Diabetes Mellitus

Summary: the purposes of the study is to determine whether blood sugar control is different between lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.


Eligibility criteria:
inclusion criteria: * patients between 18 - 79 years of age * with diagnosed type 2 diabetes for at least a year treated with stable doses of two oral antidiabetic drugs of which one is either avandia or actos for at least three months exclusion criteria: * major cardiovascular events the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
intraoperative hypotension and metabolomics in major upper gastrointestinal surgery

Conditions: the Intraoperative Hypotension

Summary: we will investigate the effect of hypotension prediction index guidance on intraoperative hypotension and metabolomics in patients undergoing major upper gastrointestinal surgery

intraoperative hypotension (ioh) has been shown to increase the risk of postoperative morbidity and mortality. the hypotension prediction index (hpi) guidance is an algorithm that can predict impending hypotension, defined as mean arterial pressure below 65mmhg. patients undergoing major upper abdominal surgery are at high risk of ioh occurrence, because the surgical procedures involve organ removal like intestinal resection and vessel or organ anastomoses or reconstruction, often associated with high blood loss. however, the effectivity of applying hpi for reducing the duration and severity of ioh and postoperative morbidity and mortality in short term within 30 days after surgery and long term within 1 year remains inconclusive. postoperative ileus (poi) generally defines absence of flatus within 72 hours after surgery. poi is known as the most important factor to slow patient recovery, increase postoperative morbidity and prolong the hospital stay following major upper abdominal surgery. metabolomics can investigate the small molecule changes in response to certain stimulus, such as different environments. metabolomics involves the comprehensive analysis of metabolites. in recent years, metabolomics has several applications in the early diagnosis and prevention of health and disease. however, the association between the poi occurrence and the metabolites in the presence and absence hpi guidance have not yet been investigated. the proposed strategy and specific objectives of this 2 years project using a randomized controlled trial are as the follows: 1. to clarify the relationship of poi occurrence to presence and absence of hpi guidance 2. to explore differences in metabolites in presence or absence of hpi guidance. 3. explore the potential metabolites associated with poi in different intraoperative environment in using hpi and no hpi guidance.

Eligibility criteria:
inclusion criteria: * elective upper gastrointestinal surgery exclusion criteria: * no laparoscopic surgery
adcc against gastric cancer cells

Conditions: Gastric Cancer

Summary: peripheral blood will be taken from the enrolled patients at national university hospital and from healthy volunteers. adcc assay will be performed for evaluating efficacy of new medicine candidates.


Eligibility criteria:
inclusion criteria: for the gastric cancer patients, patients with 21 years of age and above and younger than 80 years old who have gastric cancer can enroll in this study. for the healthy donors, healthy volunteers with 21 years of age and above and younger than 80 years old can enroll in this study. exclusion criteria: (a) age of \ 80 years old (b) pregnancy (c) decision of unsuitableness by principal investigator or physician-in-charge
fitbit and ai chatbot in sedentary primary care patients with t2d

Conditions: Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); T2DM (Type 2 Diabetes Mellitus); T2D; T2DM; Remote Patient Monitoring; Artificial Intelegence

Summary: the goal of this observational study is to evaluate the feasibility and acceptability of a 12-week intervention utilizing a fitbit and artificial intelligence (ai)-delivered diabetes self-management education and support (dsmes) with tailored text messages. the main question it aims to answer is: does providing a wearable fitness and activity tracker plus ai-tailored and dsmes improve clinical outcomes for patients with type 2 diabetes? participants will complete a baseline visit, wear a fitbit and answer text messages for 12-weeks, and complete by a final visit.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes per investigator discretion * no more than 20% of the sample will have a1c \< 7.5% (confirmed by medical record review or an a1c completed within 3 months of the screening visit) * age ≥18 years and ≤ 80 years * does not meet ada guidelines for physical activity (\< 150 minutes of aerobic exercise per week defined as any activity where the participant can talk but not sing) * has a smartphone compatible with a fitbit exclusion criteria: * completing more than 60 minutes of moderate to vigorous activity per week defined as activity where you cannot sing (moderate) or can't say more than a few words without gasping for breath (vigorous)(14) * any medical condition which, in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders. * current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12- months * any planned surgery during the study which could be considered major in the opinion of the investigator * blood disorder or dyscrasia within 3 months before screening, or the use of hydroxyurea, which, in the investigator's opinion, could interfere with the determination of hba1c * has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study, as they may interfere with the determination of hba1c. * planning to move from colorado within 3 months * current pregnancy or planning on pregnancy in the next 3 months * unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision that impacts ability to see fitbit, impaired memory) * unable to speak english as this is a small feasibility study that does not have the resources to adapt the intervention for spanish * current participation in another diabetes-related clinical trial

Keywords: type 2 diabetes artificial intelligence fitbit primary care remote patient monitoring physical activity
blood collection from heart failure patients to evaluate for galectin-3 measurement differences using various collection tubes

Conditions: To Measure Galectin-3 in Heart Failure Patients on Commercial Platforms

Summary: single-site blood collection investigation.

45 heart failure patients will be recruited. patients will provide a one-time blood sample specimen collection. theses samples will be de-identified and provided for measurement of galectin-3 on commercial platforms.

Eligibility criteria:
inclusion criteria: * heart failure patients new york heart association class able to provide (4) collection tube types subjects \> 18 years old all subjects must provide informed consent and associated documentation exclusion criteria: * subjects that cannot tolerate blood withdrawal of 4 specimens collection tube tubes (approximately 40 mls)